Charles River Laboratories International, Inc. (NYSE:CRL) insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Davide Molho also recently made the following trade(s):

  • On Tuesday, September 5th, Davide Molho sold 5,982 shares of Charles River Laboratories International stock. The shares were sold at an average price of $107.55, for a total value of $643,364.10.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) traded down 0.30% on Friday, reaching $109.79. The company’s stock had a trading volume of 60,902 shares. The firm has a market capitalization of $5.23 billion, a PE ratio of 28.93 and a beta of 0.96. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $110.59. The firm has a 50-day moving average price of $106.46 and a 200 day moving average price of $97.13.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The company had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. Charles River Laboratories International’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.20 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/06/charles-river-laboratories-international-inc-crl-insider-sells-678150-00-in-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Davidson Kempner Capital Management LP purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $10,115,000. Lord Abbett & CO. LLC purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $65,915,000. WINTON GROUP Ltd purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $16,008,000. Public Employees Retirement System of Ohio lifted its holdings in shares of Charles River Laboratories International by 1.5% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 22,383 shares of the medical research company’s stock valued at $2,264,000 after purchasing an additional 330 shares during the last quarter. Finally, Koch Industries Inc. purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $240,000. Hedge funds and other institutional investors own 95.37% of the company’s stock.

A number of research analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research note on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price objective for the company. Jefferies Group LLC reiterated a “buy” rating and set a $120.00 price objective on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Robert W. Baird reiterated a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 1st. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $99.59.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.